Home Featured Page 118

Featured

Latest

Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C

Paving the Way: Husseini Manji on Spravato’s Lessons for Psychedelic Drug Development

Josh Lipson, PhD & Roman Palitsky, MDiv, PhD: Psychedelic Harms and the Post-Psychedelic Challenges Study

Why Perimenopause Belongs in Psychedelic Research

The Psychedelic Practitioner Issue 6: Preparedness (People)

Psychedelic Research Bulletin: March 2023

Small Pharma Announces Positive Six-month Data from Phase IIa Trial of...

PT403 – Understanding the Brain: Psychedelic Neuroscience Demystified

Clearmind Medicine Announces Pricing of US$3.5 Million Public Offering

Algernon NeuroScience Announces Successful Dosing of 2nd Cohort in Phase 1...

First Avenue Ventures Life Science Fund I Invests in Diamond Therapeutics...

Algernon NeuroScience Announces U.S. SEC Qualification of Regulation A+ Tier II...

Psyence Group Announces Closing of Fourth Tranche of Private Placement and...

Reunion Neuroscience Appoints Dr. Fred Grossman to Board of Directors

Revive Therapeutics Advances MDMA Transdermal Patch Development with Purchase of MDMA...

EDITOR PICKS

Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C

Paving the Way: Husseini Manji on Spravato’s Lessons for Psychedelic Drug...

Josh Lipson, PhD & Roman Palitsky, MDiv, PhD: Psychedelic Harms and...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C

Paving the Way: Husseini Manji on Spravato’s Lessons for Psychedelic Drug Development

Josh Lipson, PhD & Roman Palitsky, MDiv, PhD: Psychedelic Harms and the Post-Psychedelic Challenges Study

Why Perimenopause Belongs in Psychedelic Research

The Psychedelic Practitioner Issue 6: Preparedness (People)

Psychedelic Research Bulletin: March 2023

Small Pharma Announces Positive Six-month Data from Phase IIa Trial of...

PT403 – Understanding the Brain: Psychedelic Neuroscience Demystified

Clearmind Medicine Announces Pricing of US$3.5 Million Public Offering

Algernon NeuroScience Announces Successful Dosing of 2nd Cohort in Phase 1...

First Avenue Ventures Life Science Fund I Invests in Diamond Therapeutics...

Algernon NeuroScience Announces U.S. SEC Qualification of Regulation A+ Tier II...

Psyence Group Announces Closing of Fourth Tranche of Private Placement and...

Reunion Neuroscience Appoints Dr. Fred Grossman to Board of Directors

Revive Therapeutics Advances MDMA Transdermal Patch Development with Purchase of MDMA...

EDITOR PICKS

Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C

Paving the Way: Husseini Manji on Spravato’s Lessons for Psychedelic Drug...

Josh Lipson, PhD & Roman Palitsky, MDiv, PhD: Psychedelic Harms and...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY